Development of a Potential Gallium-68-Labelled Radiotracer Based on DOTA-Curcumin for Colon-Rectal Carcinoma: From Synthesis to In Vivo Studies
Abstract Colorectal cancer is the third most commonly occurring cancer in men and the second most commonly occurring cancer in women worldwide. We
Lutetium-177 radioisotope targeted therapy for treatment of cancer and other diseases
By their nature, radioactive isotopes are unstable and can change to more stable forms by radioactive decay and emission of different types
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
BACKGROUND:A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. We report
Pretargeted Imaging with Gallium-68—Improving the Binding Capability by Increasing the Number of Tetrazine Motifs
Abstract The inverse electron-demand Diels-Alder reaction between 1,2,4,5-tetrazine (Tz) and trans-cyclooct-2-ene (TCO) has gained increasing attraction among extensive studies on click chemistry due
Iodine-125 seed implantation for synchronous pancreatic metastases
Iodine-125 seed implantation for synchronous pancreatic metastases from hepatocellular carcinoma: A case report and literature review. Rationale The image-guided iodine-125 seed
Technical and dosimetric aspects of iodine-125 seed reimplantation in suboptimal prostate implants
Objective: Brachytherapy employing iodine-125 seeds is an established treatment for low-risk prostate cancers. Post-implant dosimetry (PID) is an important tool for identifying suboptimal
Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
Abstract OBJECTIVE:(99m)Tc-MDP (technetium-99(m)-labeled methylene diphosphonate) has been widely used as a radiopharmaceutical for bone scintigraphy in cases of metastatic bone disease. (177)Lu
Iodine Symporter Targeting with 124I/131I Theranostics
Abstract Theranostics, a modern approach combining therapeutics and diagnostics, is among the most promising concepts in nuclear medicine for optimizing and individualizing treatments
I131 reinforces antitumor activity of metuximab by reversing epithelial–mesenchymal transition via VEGFR‐2 signaling in hepatocellular carcinoma
Abstract CD147 is highly expressed in hepatocellular carcinoma (HCC) and associated with the invasion and metastasis of HCC. The efficacy of I131‐metuximab